Latest from Mayo Clinic Cancer Center

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.
Tanios Bekaii-Saab, MD, discusses the ReDOS and IMblaze370 trials with regorafenib trials in metastatic colorectal cancer.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).
 
Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.
Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.
 
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).
Publication Bottom Border
Border Publication
x